Paradigm Biopharmaceuticals Ltd. (AU:PAR) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Paradigm Biopharmaceuticals Ltd. successfully raised $16 million through a strategic placement to support its global Phase 3 clinical trials for osteoarthritis treatment, starting in Australia and expanding to the U.S. This capital injection will also fund other strategic initiatives, enhancing shareholder value with options that could yield an additional $63 million. The company’s pro forma cash balance post-raise is expected to be $26.9 million, providing financial stability into the second half of 2025.
For further insights into AU:PAR stock, check out TipRanks’ Stock Analysis page.
